Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$1.32 +4.8%	$1.45	$0.65 ▼ $2.12	$94.15M	2.29	309,065 shs	329,091 shs
DMAC DiaMedica Therapeutics	$2.49 -4.2%	$2.85	$1.50 ▼ $4.75	$98.69M	1.69	52,729 shs	17,421 shs
MNPR Monopar Therapeutics	$0.68 +3.0%	$0.73	$0.27 ▼ $1.75	$11.43M	1.19	197,839 shs	77,544 shs
UMRX Cogent Biosciences	$6.61 +1.2%	$10.50	$0.29 ▼ $3.72	$280.72M	3.93	1.22 million shs	1.05 million shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	+4.76%	+1.54%	-19.02%	+2.33%	+14.78%
DMAC DiaMedica Therapeutics	-4.23%	-1.97%	-11.70%	-11.70%	+44.77%
MNPR Monopar Therapeutics	+4.31%	-11.95%	-10.95%	+84.99%	-47.03%
UMRX Cogent Biosciences	+1.23%	+0.92%	-1.93%	+43.38%	-40.45%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	2.7782 of 5 stars	3.5	5.0	0.0	0.0	2.0	1.7	0.6
DMAC DiaMedica Therapeutics	0.8106 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.0
MNPR Monopar Therapeutics	2.7772 of 5 stars	3.5	5.0	0.0	0.0	2.0	1.7	0.6
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	3.00	Buy	$4.75	259.85% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	181.12% Upside
MNPR Monopar Therapeutics	3.00	Buy	$2.00	194.99% Upside
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CLSD, UMRX, DMAC, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
4/11/2024	MNPR Monopar Therapeutics	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$2.00
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00
3/14/2024	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/13/2024	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
3/13/2024	CLSD Clearside Biomedical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $4.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$8.23M	11.98	N/A	N/A	($0.25) per share	-5.28
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$0.38 per share	N/A
UMRX Cogent Biosciences	$22.50M	12.48	N/A	N/A	$1.04 per share	6.36

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$32.49M	-$0.53	N/A	N/A	N/A	-394.91%	N/A	-85.31%	5/9/2024 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
MNPR Monopar Therapeutics	-$8.40M	-$0.61	N/A	N/A	N/A	N/A	-115.79%	-88.05%	5/9/2024 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Latest CLSD, UMRX, DMAC, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
3/12/2024	Q4 2023	CLSD Clearside Biomedical	-$0.10	-$0.08	+$0.02	-$0.08	$3.40 million	$6.35 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	4.42	4.42
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
MNPR Monopar Therapeutics	N/A	4.17	4.17
UMRX Cogent Biosciences	0.18	2.90	2.90

Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
DMAC DiaMedica Therapeutics	10.12%
MNPR Monopar Therapeutics	1.83%
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	9.80%
DMAC DiaMedica Therapeutics	7.20%
MNPR Monopar Therapeutics	41.60%
UMRX Cogent Biosciences	31.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	74.72 million	67.40 million	Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
MNPR Monopar Therapeutics	11	17.45 million	10.19 million	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

CLSD, UMRX, DMAC, and MNPR Headlines

Source	Headline
	Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT) markets.businessinsider.com - February 26 at 5:33 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA) markets.businessinsider.com - February 26 at 8:53 AM
	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 26 at 8:53 AM
	Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential markets.businessinsider.com - February 15 at 8:43 AM
	Cogent Biosciences Stock Soars After $225M Private Placement marketwatch.com - February 14 at 10:02 AM
	Cogent Biosciences announces oversubscribed $225M private placement msn.com - February 14 at 10:02 AM
	Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects markets.businessinsider.com - February 9 at 2:23 AM
	Citi starts Cogent Biosciences at buy, cites GI tumor drug potential msn.com - February 8 at 4:22 PM
	Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial markets.businessinsider.com - December 15 at 7:55 PM
	Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib markets.businessinsider.com - December 13 at 5:33 PM
	Dow Surges 100 Points; Cogent Biosciences Shares Plunge markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis markets.businessinsider.com - December 11 at 10:08 AM
	Cogent slumps after mid-stage data for rare disorder therapy msn.com - December 11 at 10:08 AM
	Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares markets.businessinsider.com - November 21 at 9:11 AM
	Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences markets.businessinsider.com - November 14 at 8:40 AM
	Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences markets.businessinsider.com - November 4 at 5:21 PM
	Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating markets.businessinsider.com - October 28 at 7:55 AM
	Analyst Expectations for Cogent Biosciences's Future benzinga.com - August 30 at 8:53 AM
	Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor msn.com - August 15 at 5:40 PM
	LifeSci Capital Remains a Buy on Cogent Biosciences (COGT) markets.businessinsider.com - August 8 at 3:59 PM
	Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect? msn.com - July 11 at 1:47 PM
	Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition marketwatch.com - June 13 at 11:04 PM
	9 Analysts Have This to Say About Cogent Biosciences markets.businessinsider.com - June 12 at 4:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Clearside Biomedical

NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Monopar Therapeutics

NASDAQ:MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial